Sentinel lymph node B cells can predict disease-free survival in breast cancer patients.

We also applied the same threshold for CD20 + B cells (6200 per mm 2 area) from the discovery cohort in Kaplan–Meier analysis of this validation cohort and found highly significant impact on clinical outcome with 5 year DFS of 20% for CD20 < 6200, and 81.8% 5 year DFS for CD20 ≥ 6200 (log-rank p < 0.005, Fig. 4b ).

also in 132,142 other papers